LONDON April 25, 2012
Berg Pharma will use the BT for Life Sciences R&D cloud service as the de facto standard for running Berg’s unique Interrogative Biology® platform. BT for Life Sciences R&D, unveiled at the 10th Bio-IT World meeting, is the first cloud service designed to enable collaboration within the life sciences industry for increased R&D productivity.
BT for Life Sciences R&D is being developed to become a secure and segregated platform for scientists in pharmaceutical, biotech, devices & diagnostics companies as well as in academia and government. It will enable Berg Pharma to maximize its late-stage clinical trial activity and continue research and development of early-stage technologies in CNS (central nervous system) and metabolic diseases.
Niven R. Narain
About Berg Pharma
BT is one of the world’s leading providers of communications services and solutions, serving customers in more than 170 countries. Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to its customers for use at home, at work and on the move; broadband and internet products and services and converged fixed/mobile products and services. BT consists principally of four lines of business: BT Global Services, BT Retail, BT Wholesale and Openreach.
31 March 2011